1
|
Montagnaro S, Longo M, Pacilio M, Indovina P, Roberti A, De Martino L, Iovane G, Pagnini U. Feline herpesvirus-1 down-regulates MHC class I expression in an homologous cell system. J Cell Biochem 2009; 106:179-85. [PMID: 19009565 DOI: 10.1002/jcb.21986] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
Cytotoxic T lymphocytes (CTLs) are an essential component of the immune defense against many virus infections. CTLs recognize viral peptides in the context of the major histocompatibility complex (MHC) class I molecules on the surface of infected cells. Many viruses have evolved mechanisms to interfere with MHC class I expression as a means of evading the host immune response. In the present research we have studied the effect of in vitro Feline Herpesvirus 1 (FeHV-1) infection on MHC class I expression. The results of this study demonstrate that FeHV-1 down regulates surface expression of MHC class I molecules on infected cells, presumably to evade cytotoxic T-cell recognition and, perhaps, attenuate induction of immunity. Sensitivity to UV irradiation and insensitivity to a viral DNA synthesis inhibitor, like phosphonacetic acid, revealed that immediate early or early viral gene(s) are responsible. Use of the protein translation inhibitor cycloheximide confirmed that an early gene is primarily responsible.
Collapse
Affiliation(s)
- S Montagnaro
- Department of Pathology and animal Health, School of Veterinary Medicine, University of Naples Federico II, Via Delpino no 1, 80137 Naples, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
2
|
Reggeti F, Bienzle D. Alloimmunity does not protect from challenge with the feline immunodeficiency virus. Vet Immunol Immunopathol 2008; 124:152-62. [PMID: 18471896 DOI: 10.1016/j.vetimm.2008.03.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2008] [Revised: 02/27/2008] [Accepted: 03/07/2008] [Indexed: 10/22/2022]
Abstract
Immune responses against polymorphic host molecules incorporated into lentiviral envelopes during cell budding have induced protection against primate immunodeficiency virus infection. Dendritic cells (DCs) express high levels of MHC molecules and are infectable by lentiviruses. Therefore, in this pilot study we addressed the hypothesis that immunization of cats with allogeneic DC would induce immune responses that protect against challenge with the feline immunodeficiency virus. Two groups of 3 cats each received 3 subcutaneous injections of allogeneic or autologous DC, and were then challenged with viruses propagated in the immunizing DC. Infection status and lymphocyte parameters of cats were assessed during 6 weeks after challenge. MHC II antigens were incorporated into viral particles as identified by Western blot; and antibodies reactive with MHC class II antigens were detected in the serum of cats immunized with allogeneic but not autologous DC. After challenge, all cats had proviral DNA in blood leukocytes from 2 weeks post-challenge onward and seroconverted. Cats immunized with allogeneic DC maintained higher total and CD21(+) lymphocyte concentrations, and higher CD4(+)/CD8(+) lymphocyte ratios; however, these differences were not significantly different from cats that received autologous DC immunizations. Plasma viral load was not significantly different between groups of cats (p=0.204). These results suggest that immunization of cats with allogeneic DC does not induce protective immunity against FIV infection.
Collapse
Affiliation(s)
- F Reggeti
- Department of Pathobiology, University of Guelph, Guelph, ON N1G 2W1, Canada
| | | |
Collapse
|
3
|
FIV as a Model for HIV: An Overview. IN VIVO MODELS OF HIV DISEASE AND CONTROL 2007. [PMCID: PMC7121254 DOI: 10.1007/0-387-25741-1_7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Animal models for human immunodeficiency virus (HIV) infection play a key role in understanding the pathogenesis of AIDS and the development of therapeutic agents and vaccines. As the only lentivirus that causes an immunodeficiency resembling that of HIV infection, in its natural host, feline immunodeficiency virus (FIV) has been a unique and powerful model for AIDS research. FIV was first described in 1987 by Niels Pedersen and co-workers as the causative agent for a fatal immunodeficiency syndrome observed in cats housed in a cattery in Petaluma, California. Since this landmark observation, multiple studies have shown that natural and experimental infection of cats with biological isolates of FIV produces an AIDS syndrome very similar in pathogenesis to that observed for human AIDS. FIV infection induces an acute viremia associated with Tcell alterations including depressed CD4 :CD8 T-cell ratios and CD4 T-cell depletion, peripheral lymphadenopathy, and neutropenia. In later stages of FIV infection, the host suffers from chronic persistent infections that are typically self-limiting in an immunocompetent host, as well as opportunistic infections, chronic diarrhea and wasting, blood dyscracias, significant CD4 T-cell depletion, neurologic disorders, and B-cell lymphomas. Importantly, chronic FIV infection induces a progressive lymphoid and CD4 T-cell depletion in the infected cat. The primary mode of natural FIV transmission appears to be blood-borne facilitated by fighting and biting. However, experimental infection through transmucosal routes (rectal and vaginal mucosa and perinatal) have been well documented for specific FIV isolates. Accordingly, FIV disease pathogenesis exhibits striking similarities to that described for HIV-1 infection.
Collapse
|
4
|
Pistello M, Matteucci D, Bonci F, Isola P, Mazzetti P, Zaccaro L, Merico A, Del Mauro D, Flynn N, Bendinelli M. AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: protection from an intraclade challenge administered systemically or mucosally by an attenuated vaccine. J Virol 2003; 77:10740-50. [PMID: 14512524 PMCID: PMC224962 DOI: 10.1128/jvi.77.20.10740-10750.2003] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Feline immunodeficiency virus (FIV) infection of domestic cats represents a valuable system through which to investigate criteria for antilentiviral vaccines in a natural host species. Here, we examined whether vaccination with a strain of FIV attenuated as a result of prolonged growth in vitro could protect against a fully virulent, highly heterologous intraclade challenge. The results indicated that the vaccine virus produced a low-grade infection with no detectable pathological effects and afforded a long-lasting sterilizing immunity if the challenge was delivered intraperitoneally as cell-free virus but not against a cell-associated intravaginal challenge. In the latter case, however, the replication and pathological consequences of the challenge virus were markedly suppressed. Together with similar results obtained in rhesus monkey models, these findings should give impulse to the development of attenuated FIV vaccines to be tested in controlled studies in field cats. Field studies may provide answers to some of the existing safety concerns surrounding attenuated AIDS vaccines in humans.
Collapse
Affiliation(s)
- Mauro Pistello
- Retrovirus Center and Virology Section, Department of Experimental Pathology, University of Pisa, Pisa, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Giannecchini S, Isola P, Sichi O, Matteucci D, Pistello M, Zaccaro L, Del Mauro D, Bendinelli M. AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: failure to protect and possible enhancement of challenge infection by four cell-based vaccines prepared with autologous lymphoblasts. J Virol 2002; 76:6882-92. [PMID: 12072489 PMCID: PMC136316 DOI: 10.1128/jvi.76.14.6882-6892.2002] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Immunogenicity and protective activity of four cell-based feline immunodeficiency virus (FIV) vaccines prepared with autologous lymphoblasts were investigated. One vaccine was composed of FIV-infected cells that were paraformaldehyde fixed at the peak of viral expression. The other vaccines were attempts to maximize the expression of protective epitopes that might become exposed as a result of virion binding to cells and essentially consisted of cells mildly fixed after saturation of their surface with adsorbed, internally inactivated FIV particles. The levels of FIV-specific lymphoproliferation exhibited by the vaccinees were comparable to the ones previously observed in vaccine-protected cats, but antibodies were largely directed to cell-derived constituents rather than to truly viral epitopes and had very poor FIV-neutralizing activity. Moreover, under one condition of testing, some vaccine sera enhanced FIV replication in vitro. As a further limit, the vaccines proved inefficient at priming animals for anamnestic immune responses. Two months after completion of primary immunization, the animals were challenged with a low dose of homologous ex vivo FIV. Collectively, 8 of 20 vaccinees developed infection versus one of nine animals mock immunized with fixed uninfected autologous lymphoblasts. After a boosting and rechallenge with a higher virus dose, all remaining animals became infected, thus confirming their lack of protection.
Collapse
MESH Headings
- AIDS Vaccines/administration & dosage
- AIDS Vaccines/immunology
- Acquired Immunodeficiency Syndrome/prevention & control
- Animals
- Antibodies, Viral/blood
- Antigens, Viral/immunology
- Cats
- Disease Models, Animal
- Feline Acquired Immunodeficiency Syndrome/prevention & control
- Female
- Immunization, Secondary
- Immunodeficiency Virus, Feline/immunology
- Immunodeficiency Virus, Feline/physiology
- Leukocytes, Mononuclear/immunology
- Leukocytes, Mononuclear/transplantation
- Leukocytes, Mononuclear/virology
- Lymphocyte Activation
- RNA, Viral/blood
- Transplantation, Autologous
- Vaccination
- Viral Vaccines/administration & dosage
- Viral Vaccines/immunology
Collapse
Affiliation(s)
- Simone Giannecchini
- Retrovirus Center and Virology Section, Department of Biomedicine, University of Pisa, Pisa, Italy
| | - Patrizia Isola
- Retrovirus Center and Virology Section, Department of Biomedicine, University of Pisa, Pisa, Italy
| | - Olimpia Sichi
- Retrovirus Center and Virology Section, Department of Biomedicine, University of Pisa, Pisa, Italy
| | - Donatella Matteucci
- Retrovirus Center and Virology Section, Department of Biomedicine, University of Pisa, Pisa, Italy
| | - Mauro Pistello
- Retrovirus Center and Virology Section, Department of Biomedicine, University of Pisa, Pisa, Italy
| | - Lucia Zaccaro
- Retrovirus Center and Virology Section, Department of Biomedicine, University of Pisa, Pisa, Italy
| | - Daniela Del Mauro
- Retrovirus Center and Virology Section, Department of Biomedicine, University of Pisa, Pisa, Italy
| | - Mauro Bendinelli
- Retrovirus Center and Virology Section, Department of Biomedicine, University of Pisa, Pisa, Italy
- Corresponding author. Mailing address: Dipartimento di Biomedicina, Università di Pisa, Via San Zeno 37, I-56127 Pisa, Italy. Phone: 39-050-553562. Fax: 39-050-559455. E-mail:
| |
Collapse
|
6
|
Pistello M, Moscardini M, Mazzetti P, Bonci F, Zaccaro L, Isola P, Freer G, Specter S, Matteucci D, Bendinelli M. Development of feline immunodeficiency virus ORF-A (tat) mutants: in vitro and in vivo characterization. Virology 2002; 298:84-95. [PMID: 12093176 DOI: 10.1006/viro.2002.1442] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
A functional ORF-A is essential for efficient feline immunodeficiency virus replication in lymphocytes. We have characterized a series of mutants of the Petaluma strain, derived from p34TF10 and having different combinations of stop codons and increasingly long deletions in ORF-A. Six clones proved fully replicative in fibroblastoid Crandell feline kidney cells and monocyte-derived macrophage cultures but failed to replicate in T cell lines and primary lymphoblasts. Cats inoculated with three selected mutants had considerably milder infections than controls given intact ORF-A virus. In vivo, the mutants maintained growth properties similar to those in vitro for at least 7 months, except that replication in lymphoid cells was strongly reduced but not ablated. One mutant underwent extensive ORF-A changes without, however, reverting to wild-type. Antiviral immune responses were feeble in all cats, suggesting that viral loads were too low to represent a sufficiently powerful antigenic stimulus.
Collapse
Affiliation(s)
- M Pistello
- Retrovirus Center and Virology Section, University of Pisa, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Finerty S, Stokes CR, Gruffydd-Jones TJ, Hillman TJ, Barr FJ, Harbour DA. Targeted lymph node immunization can protect cats from a mucosal challenge with feline immunodeficiency virus. Vaccine 2001; 20:49-58. [PMID: 11567745 DOI: 10.1016/s0264-410x(01)00323-1] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
With the rapid spread of human immunodeficiency virus (HIV) infection worldwide it is clear that effective strategies for mucosal vaccination against lentiviruses are urgently required. The aim of the present study is to determine whether protective immune responses against a mucosal challenge by feline immunodeficiency virus (FIV) can be elicited by targeting the immunization to the medial iliac lymph nodes--the principal site of migration of cells from the genital and rectal mucosa. Cats were challenged with homologous FIV via the rectal route. Targeted lymph node immunization was found to be an effective route of immunization eliciting both humoral and proliferative responses to peptide-based and fixed cell vaccines. Vaccination with fixed virus infected cells elicited protection against a cell-free mucosal FIV challenge. In addition, some cats vaccinated with fixed uninfected cells also remained uninfected following a cell-associated FIV challenge.
Collapse
MESH Headings
- Administration, Rectal
- Amino Acid Sequence
- Animals
- Antibodies, Viral/biosynthesis
- Antibodies, Viral/immunology
- Antigens, Viral/administration & dosage
- Antigens, Viral/chemistry
- Antigens, Viral/immunology
- Cats
- Cells, Cultured/transplantation
- Cells, Cultured/virology
- Drug Evaluation
- Feline Acquired Immunodeficiency Syndrome/immunology
- Feline Acquired Immunodeficiency Syndrome/prevention & control
- Gene Products, gag/immunology
- Glycoproteins/administration & dosage
- Glycoproteins/chemistry
- Glycoproteins/immunology
- Immunodeficiency Virus, Feline/immunology
- Immunodeficiency Virus, Feline/physiology
- Injections, Intralymphatic
- Lymph Nodes/immunology
- Molecular Sequence Data
- Peptide Fragments/administration & dosage
- Peptide Fragments/chemistry
- Peptide Fragments/immunology
- Pilot Projects
- T-Lymphocytes/transplantation
- T-Lymphocytes/virology
- Vaccination/methods
- Vaccination/veterinary
- Vaccines, Subunit/administration & dosage
- Vaccines, Subunit/immunology
- Vaccines, Synthetic/administration & dosage
- Vaccines, Synthetic/immunology
- Viral Envelope Proteins/administration & dosage
- Viral Envelope Proteins/chemistry
- Viral Envelope Proteins/immunology
- Viral Vaccines/administration & dosage
- Viral Vaccines/immunology
Collapse
Affiliation(s)
- S Finerty
- Department of Clinical Veterinary Science, University of Bristol, Langford, BS40 5DU, Bristol, UK.
| | | | | | | | | | | |
Collapse
|
8
|
Giannecchini S, Del Mauro D, Matteucci D, Bendinelli M. AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: reevaluation of neutralizing antibody levels elicited by a protective and a nonprotective vaccine after removal of antisubstrate cell antibodies. J Virol 2001; 75:4424-9. [PMID: 11287594 PMCID: PMC114190 DOI: 10.1128/jvi.75.9.4424-4429.2001] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
In the feline immunodeficiency virus system, immunization with a fixed-infected-cell vaccine conferred protection against virulent homologous challenge but the immune effectors involved remained elusive. In particular, few or no neutralizing antibodies were detected in sera from vaccinated cats. Here we show that, when preadsorbed with selected feline cells, the same sera revealed clearly evident virus-neutralizing activity. Because high titers of neutralizing antibody in cell-adsorbed sera from 23 cats immunized with fixed-infected-cell or whole-inactivated-virus vaccines correlated with protection, it is likely that they were more important for protection than formerly realized. In vitro, the fixed-cell vaccine efficiently removed neutralizing antibody from immune sera while the whole-inactivated-virus vaccine was much less effective.
Collapse
Affiliation(s)
- S Giannecchini
- Department of Biomedicine and Retrovirus Center, University of Pisa, Pisa, Italy
| | | | | | | |
Collapse
|
9
|
Hartaningsih N, Dharma DM, Soeharsono S, Wilcox GE. The induction of a protective immunity against Jembrana disease in cattle by vaccination with inactivated tissue-derived virus antigens. Vet Immunol Immunopathol 2001; 78:163-76. [PMID: 11182155 DOI: 10.1016/s0165-2427(00)00265-8] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The ability to induce a protective immunity against Jembrana disease, an acute lentivirus disease of Bali cattle (Bos javanicus) present in Indonesia, was investigated. A protective immune response was induced in cattle by vaccination with virus-containing plasma and spleen tissue derived from acutely affected cattle. The virus was inactivated with Triton X-100 and emulsified in either incomplete Freund's adjuvant or a mineral oil adjuvant (MOA). The vaccination procedure suppressed the duration and severity of the disease but did not completely prevent the development of disease in animals challenged with 100 infectious doses of virus.
Collapse
Affiliation(s)
- N Hartaningsih
- Bali Cattle Disease Investigation Unit, BPPH, PO Box 3322, Denpasar, Bali, Indonesia
| | | | | | | |
Collapse
|
10
|
Matteucci D, Poli A, Mazzetti P, Sozzi S, Bonci F, Isola P, Zaccaro L, Giannecchini S, Calandrella M, Pistello M, Specter S, Bendinelli M. Immunogenicity of an anti-clade B feline immunodeficiency fixed-cell virus vaccine in field cats. J Virol 2000; 74:10911-9. [PMID: 11069985 PMCID: PMC113170 DOI: 10.1128/jvi.74.23.10911-10919.2000] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Attempts at vaccine development for feline immunodeficiency virus (FIV) have been extensive, both because this is a significant health problem for cats and because FIV may be a useful vaccine model for human immunodeficiency virus. To date, only modest success, producing only short-term protection, has been achieved for vaccine trials in controlled laboratory settings. It is unclear how relevant such experiments are to prevention of natural infection. The current study used a vaccine that employs cell-associated FIV-M2 strain fixed with paraformaldehyde. Subject cats were in a private shelter where FIV was endemic, a prevalence of 29 to 58% over an 8-year observation period. Cats roamed freely from the shelter through the surrounding countryside but returned for food and shelter. After ensuring that cats were FIV negative, they were immunized using six doses of vaccine over a 16-month period and observed for 28 months after the initiation of immunization. Twenty-six cats (12 immunized and 14 nonimmunized controls) were monitored for a minimum of 22 months. Immunized cats did not experience significant adverse effects from immunization and developed both antibodies and cellular immunity to FIV, although individual responses varied greatly. At the conclusion of the study, 0 of 12 immunized cats had evidence of FIV infection, while 5 of 14 control cats were infected. Thus, the vaccine was safe and immunogenic and did not transmit infection. Furthermore, vaccinated cats did not develop FIV infection in a limited clinical trial over an extended time period. Thus, the data suggest that a fixed, FIV-infected cell vaccine has potential for preventing natural FIV infection in free-roaming cats.
Collapse
Affiliation(s)
- D Matteucci
- Department of Biomedicine, Retrovirus Center and Virology Section, University of Pisa, I-56127 Pisa, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Finerty S, Stokes CR, Gruffydd-Jones TJ, Hillman TJ, Reeves NA, Whiting CV, Schaaper WM, Dalsgaard K, Harbour DA. Mucosal immunization with experimental feline immunodeficiency virus (FIV) vaccines induces both antibody and T cell responses but does not protect against rectal FIV challenge. Vaccine 2000; 18:3254-65. [PMID: 10869770 DOI: 10.1016/s0264-410x(00)00131-6] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Feline immunodeficiency virus (FIV) is a natural lentiviral pathogen of cats which can be experimentally transmitted via rectal and vaginal routes--the major routes of human immunodeficiency virus type 1 transmission in man. An important objective for lentiviral research is the development of vaccine strategies which generate good mucosal immune responses capable of giving protection from a mucosal virus challenge. The experimental vaccines employed in this study were based on (a) a peptide from the third variable region of the FIV envelope glycoprotein and (b) fixed whole FIV, Glasgow-8 strain. Adjuvants used were Quil A and cholera toxin for mucosal administration and incomplete Freund's adjuvant and immune stimulating complexes for subcutaneous injection. Mucosal immunization was given by rectal and intranasal routes. Both antibody and proliferative responses were elicited by mucosal immunization and cholera toxin was found to be a good mucosal adjuvant. The addition of a lipo thioester to the FIV peptide improved IgG and IgA responses upon parenteral administration. However, no protection from a rectal FIV challenge was achieved.
Collapse
Affiliation(s)
- S Finerty
- Department of Clinical Veterinary Science, University of Bristol, Langford, BS40 5DU, Bristol, UK.
| | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Lockridge KM, Chien M, Dean GA, Stefano Cole K, Montelaro RC, Luciw PA, Sparger EE. Protective immunity against feline immunodeficiency virus induced by inoculation with vif-deleted proviral DNA. Virology 2000; 273:67-79. [PMID: 10891409 DOI: 10.1006/viro.2000.0395] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
To determine whether live-attenuated feline immunodeficiency virus (FIV) proviral DNA will induce protective immunity, a plasmid clone constructed with a FIV provirus containing a deletion in the viral accessory gene vif (FIV-pPPR-Deltavif) was inoculated as proviral DNA into four cats by the intramuscular route. After 43 weeks, these cats were boosted with the same proviral plasmid. Analysis of peripheral blood mononuclear cells at several time points after the primary and booster inoculations revealed no detectable virus or proviral DNA. At 6 weeks after the booster, immunized cats and additional naive control cats were challenged with a cell-free preparation of the infectious biological isolate FIV-PPR by the intraperitoneal route. Virus was detected after challenge in unvaccinated control cats but not in any of the FIV-pPPR-Deltavif-immunized cats. Both FIV Gag- and Env-specific cytotoxic T lymphocyte (CTL) activities were detected in peripheral blood cells of control cats after challenge infection, whereas only one of four cats immunized with FIV-pPPR-Deltavif DNA exhibited a measurable CTL response to Env following challenge. Although anti-Gag antibodies were not detected after both proviral DNA inoculation and challenge, anti-Env antibodies were found in FIV-pPPR-Deltavif-immunized cats after vaccination as well as after challenge. These findings indicate that inoculation with FIV-pPPR-Deltavif proviral DNA induced resistance to challenge with infectious FIV and that a vif deletion mutant may provide a relatively safe attenuated lentiviral vaccine.
Collapse
MESH Headings
- Animals
- Antibodies, Viral/immunology
- Antigens, Viral/immunology
- Cats
- DNA, Viral/administration & dosage
- DNA, Viral/analysis
- DNA, Viral/genetics
- Gene Deletion
- Gene Products, env/immunology
- Gene Products, gag/immunology
- Gene Products, vif/genetics
- Genome, Viral
- Immunodeficiency Virus, Feline/genetics
- Immunodeficiency Virus, Feline/immunology
- Immunodeficiency Virus, Feline/physiology
- Lentivirus Infections/immunology
- Lentivirus Infections/prevention & control
- Lentivirus Infections/virology
- Lymphocyte Count
- Proviruses/genetics
- T-Lymphocytes, Cytotoxic/immunology
- Time Factors
- Vaccines, DNA/genetics
- Vaccines, DNA/immunology
- Viral Vaccines/genetics
- Viral Vaccines/immunology
Collapse
Affiliation(s)
- K M Lockridge
- Departments of Medicine and Epidemiology, University of California, Davis, California, 95616, USA
| | | | | | | | | | | | | |
Collapse
|
13
|
Pistello M, Matteucci D, Cammarota G, Mazzetti P, Giannecchini S, Del Mauro D, Macchi S, Zaccaro L, Bendinelli M. Kinetics of replication of a partially attenuated virus and of the challenge virus during a three-year intersubtype feline immunodeficiency virus superinfection experiment in cats. J Virol 1999; 73:1518-27. [PMID: 9882357 PMCID: PMC103976 DOI: 10.1128/jvi.73.2.1518-1527.1999] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The effects of preinfecting cats with a partially attenuated feline immunodeficiency virus (FIV) on subsequent infection with a fully virulent FIV belonging to a different subtype were investigated. Eight specific-pathogen-free cats were preinfected with graded doses of a long-term in vitro-cultured cell-free preparation of FIV Petaluma (FIV-P, subtype A). FIV-P established a low-grade or a silent infection in the inoculated animals. Seven months later, the eight preinfected cats and two uninfected cats were challenged with in vivo-grown FIV-M2 (subtype B) and periodically monitored for immunological and virological status. FIV-P-preinfected cats were not protected from acute infection by FIV-M2, and the sustained replication of this virus was accompanied by a reduction of FIV-P viral loads in the peripheral blood mononuclear cells and plasma. However, from 2 years postchallenge (p.c.) until 3 years p.c., when the experiment was terminated, preinfected cats exhibited reduced total viral burdens, and some also exhibited a diminished decline of circulating CD4(+) T lymphocytes relative to control cats infected with FIV-M2 alone. Interestingly, most of the virus detected in challenged cats at late times p.c. was of FIV-P origin, indicating that the preinfecting, attenuated virus had become largely predominant. By the end of follow-up, two challenged cats had no FIV-M2 detectable in the tissues examined. The possible mechanisms underlying the interplay between the two viral populations are discussed.
Collapse
Affiliation(s)
- M Pistello
- Retrovirus Center and Virology Section, Department of Biomedicine, University of Pisa, Pisa, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Mazzetti P, Giannecchini S, Del Mauro D, Matteucci D, Portincasa P, Merico A, Chezzi C, Bendinelli M. AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: detailed analysis of the humoral immune response to a protective vaccine. J Virol 1999; 73:1-10. [PMID: 9847300 PMCID: PMC103801 DOI: 10.1128/jvi.73.1.1-10.1999] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The feline immunodeficiency virus (FIV) cat model is extensively used to investigate possible vaccination approaches against AIDS in humans. Although consistent levels of protection have been achieved with FIV, as with other model systems, by immunizing with whole inactivated virus or fixed infected cells, the mechanisms responsible for protection are elusive. In previous studies we showed that cats immunized with a vaccine consisting of fixed infected cells were protected or unprotected against cell-free or cell-associated FIV challenge depending on the time interval between completion of vaccination and challenge. In an attempt to define possible humoral immune correlates of protection, selected sera harvested at the times of challenge from such cats were examined for anti-FIV-antibody titers and properties by using binding and functional immunological assays. Binding assays included quantitative Western blotting, enzyme-linked tests for antibodies to FIV glycoproteins and immunodominant linear epitopes, and tests for measuring conformation dependence and avidity of anti-viral-envelope antibodies. Functional assays included virus neutralization performed with two different cell substrates, complement- and antibody-dependent virolysis, blocking of reverse transcriptase, and an assay that measured the ability of sera to prevent FIV growth in cocultures of infected and uninfected cells. Despite the wide spectrum of parameters investigated, no correlation between vaccine-induced protection and the humoral parameters measured was noted.
Collapse
Affiliation(s)
- P Mazzetti
- Department of Biomedicine and Retrovirus Center, University of Pisa, Pisa, Italy
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Karlas JA, Siebelink KH, v Peer MA, Huisman W, Rimmelzwaan GF, Osterhaus AD. Accelerated viraemia in cats vaccinated with fixed autologous FIV-infected cells. Vet Immunol Immunopathol 1998; 65:353-65. [PMID: 9839884 DOI: 10.1016/s0165-2427(98)00166-4] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
We have vaccinated cats with fixed autologous FIV infected PBMC to determine whether autologous presentation of antigen is capable of inducing a protective immune response against homologous challenge. To this end autologous PBMC were infected with a FIV molecular clone (19k1). When infection was established, cells were inactivated by dialysis against paraformaldehyde. Upon vaccination, cats developed a virus specific immune response as measured by ELISA against the Gag protein of FIV. No antibodies against the envelope protein were detected with a peptide ELISA. Virus neutralizing antibodies however could be detected with a neutralization assay based on infection of CrFK cells, but not in an assay based on infection of primary T-cells. Although vaccination led to the induction of these virus-specific immune responses, vaccinated cats were not protected against homologous challenge but showed an accelerated viraemia upon infection. This was shown both by PCR and cell-associated viral load. The possible mechanisms underlying this observation are discussed in this paper.
Collapse
Affiliation(s)
- J A Karlas
- Institute of Virology, Erasmus University Rotterdam, The Netherlands
| | | | | | | | | | | |
Collapse
|
16
|
Chiarantini L, Matteucci D, Pistello M, Mancini U, Mazzetti P, Massi C, Giannecchini S, Lonetti I, Magnani M, Bendinelli M. AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: homologous erythrocytes as a delivery system for preferential immunization with putative protective antigens. CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY 1998; 5:235-41. [PMID: 9521149 PMCID: PMC121364 DOI: 10.1128/cdli.5.2.235-241.1998] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Feline immunodeficiency virus (FIV) is a useful model for testing of criteria for AIDS vaccine development. In the protocol we adopted, we used a primary isolate of FIV as a source of antigen and, for challenge, plasma from cats infected with the homologous virus never passaged in vitro. Cat erythrocytes (RBC) were coated with the surface components of freshly harvested and purified FIV by means of biotin-avidin-biotin bridges and used to immunize specific-pathogen-free cats (four doses at monthly intervals; total amount of FIV antigen administered per cat, approximately 14 microg). Immunized cats developed moderate levels of antibodies directed mainly to surface components of the virion and clearly evident lymphoproliferative responses. Four months after the last dose of immunogen, FIV-immunized cats and control cats immunized with bovine serum albumin-coated RBC were challenged. Judged from the results of the subsequent 12-month follow-up, FIV-immunized cats exhibited at least some degree of protection. However, following rechallenge, most of the FIV-immunized animals became virus positive in spite of a booster immunogen dose given 2 months before the second challenge.
Collapse
Affiliation(s)
- L Chiarantini
- Department of Biomedicine, University of Pisa, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Huisman W, Karlas JA, Siebelink KH, Huisman RC, de Ronde A, Francis MJ, Rimmelzwaan GF, Osterhaus AD. Feline immunodeficiency virus subunit vaccines that induce virus neutralising antibodies but no protection against challenge infection. Vaccine 1998; 16:181-7. [PMID: 9607028 DOI: 10.1016/s0264-410x(97)00184-9] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
Three experimental vaccines against feline immunodeficiency virus (FIV), all based on viral antigens presented via immune stimulating complexes (iscoms), were tested for their capacity to induce protection in cats from FIV infection. The respective vaccines consisted of FIV propagated in Crandell feline kidney (CrFK) cells (FIV-iscoms); FIV-iscoms spiked with recombinant vaccinia virus expressed FIV envelope glycoprotein incorporated into iscoms (FIV-iscoms + vGR657x15-iscoms) and vGR657x15-iscoms spiked with recombinant FIV Gag protein incorporated into iscoms (vGR657x15-iscoms + FIV-Gag-iscoms). Simian immunodeficiency virus envelope glycoprotein incorporated into iscoms, iscoms prepared with uninfected CrFK cells, and PBS served as controls. All cats vaccinated with vGR657x15-iscoms combined with FIV-iscoms or FIV-Gag-iscoms developed Env-specific plasma antibody responses. These antibodies neutralised FIV infection in CrFK cells, but failed to neutralise FIV infection in primary feline thymocytes. FIV-iscoms induced poor Env-specific responses and only one out of six cats developed antibodies that neutralised FIV in the CrFK cell based assay. Four weeks after challenge all cats proved to be infected, showing that none of the vaccine preparations provided protection. In contrast, 2 weeks after infection, virus infected peripheral blood mononuclear cells were only observed in cats vaccinated with FIV-iscoms + vGR657x15-iscoms or CrFK-iscoms and to a lesser extent in cats vaccinated with FIV-iscoms and vGR657x15-iscoms + FIV-Gag-iscoms, but not in cats vaccinated with SIV-iscoms or PBS. The differences found in cell associated virus loads amongst the respective groups are discussed in the light of antibody mediated enhancement of infectivity and protective effects provided by Gag-specific T cell responses.
Collapse
Affiliation(s)
- W Huisman
- Institute of Virology, Erasmus University Rotterdam, The Netherlands
| | | | | | | | | | | | | | | |
Collapse
|
18
|
Matteucci D, Pistello M, Mazzetti P, Giannecchini S, Del Mauro D, Lonetti I, Zaccaro L, Pollera C, Specter S, Bendinelli M. Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection conferred by a fixed-cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted. J Virol 1997; 71:8368-76. [PMID: 9343192 PMCID: PMC192298 DOI: 10.1128/jvi.71.11.8368-8376.1997] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Cats immunized with cells infected with a primary isolate of feline immunodeficiency virus (FIV) and fixed with paraformaldehyde were challenged with cell-free or cell-associated homologous virus obtained ex vivo. Complete protection was observed in animals challenged with cell-free virus 4 months after completion of vaccination (p.v.) or with cell-associated virus 12 months p.v. In contrast, no protection was observed in cats challenged with cell-free virus 12 or 28 months p.v. or with cell-associated virus 37.5 months p.v. Prior to the 28- and 37.5-month challenges, the animals had received a booster dose of vaccine that had elicited a robust anamnestic immune response. These results show that vaccine-induced protection against ex vivo FIV is achievable but is relatively short-lived and can be difficult to boost.
Collapse
Affiliation(s)
- D Matteucci
- Department of Biomedicine, University of Pisa, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|